Akram Muhammad, Daniyal Muhammad, Sultana Sabira, Owais Aymen, Akhtar Naheed, Zahid Rabia, Said Fahad, Bouyahya Abdelhakim, Ponomarev Evgeny, Ali Shariat Mohammad, Thiruvengadam Muthu
Department of Eastern Medicine, Directorate of Medical Sciences, Government College University Faisalabad, Pakistan.
TCM and Ethnomedicine Innovation & Development International Laboratory, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Clin Chim Acta. 2021 Jan;512:142-155. doi: 10.1016/j.cca.2020.11.003. Epub 2020 Nov 11.
Rheumatoid arthritis (RA) is a serious disorder of the joints affecting 1 or 2% of the population aged between 20 and 50 years worldwide. RA is the foremost cause of disability in developing and Western populations. It is an autoimmune disease-causing inflammation and pain involving synovial joints. Pro-inflammatory markers, including cytokines, such as interleukin -1 (IL-1), IL-6, IL-7, IL-8, and tumor necrosis factor-α (TNF-α) are involved in RA. RA treatment involves TNF-α blockade, B cell therapy, IL-1 and IL-6 blockade, and angiogenesis inhibition. Synthetic drugs available for the treatment of RA include disease-modifying anti-rheumatic drugs (DMARD), such as cyclophosphamide, sulfasalazine, methotrexate, nonsteroidal anti-inflammatory drugs (NSAIDs), and intramuscular gold. These agents induce adverse hepatorenal effects, hypertension, and gastric ulcers. We found that patients diagnosed with chronic pain, as in RA, and those refractory to contemporary management are most likely to seek traditional medicine. Approximately 60-90% of patients with arthritis use traditional medicines. Therefore, the efficacy and safety of these traditional medicines need to be established. The treatment for RA entails a comprehensive multidisciplinary strategy to reduce pain and inflammation and to restore the activity of joints. The potential medicinal plants exhibiting anti-arthritic and anti-rheumatic pharmacological activity are reviewed here.
类风湿性关节炎(RA)是一种严重的关节疾病,全球20至50岁人群中1%至2%的人受其影响。在发展中地区和西方人群中,RA是导致残疾的首要原因。它是一种自身免疫性疾病,会引起滑膜关节的炎症和疼痛。促炎标志物,包括细胞因子,如白细胞介素-1(IL-1)、IL-6、IL-7、IL-8和肿瘤坏死因子-α(TNF-α)都与RA有关。RA的治疗包括TNF-α阻断、B细胞疗法、IL-1和IL-6阻断以及血管生成抑制。可用于治疗RA的合成药物包括改善病情抗风湿药(DMARD),如环磷酰胺、柳氮磺胺吡啶、甲氨蝶呤、非甾体抗炎药(NSAIDs)和肌肉注射金。这些药物会引发肝肾不良反应、高血压和胃溃疡。我们发现,被诊断患有慢性疼痛(如RA)且对现代治疗方法无效的患者最有可能寻求传统医学治疗。大约60%至90%的关节炎患者使用传统药物。因此,需要确定这些传统药物的疗效和安全性。RA的治疗需要采取全面的多学科策略来减轻疼痛和炎症,并恢复关节的活动能力。本文综述了具有抗关节炎和抗风湿药理活性的潜在药用植物。